Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toru Wakamatsu has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability

    by Haruki Matsuoka, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Hideaki Sabe, Yusuke Yoshimura, Haruna Takami, Rie Suzuki, et al.

    Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive soft tissue sarcoma of presumed peripheral nerve sheath origin, for which effective systemic therapies remain limited. The biological mechanisms underlying its progression and therapeutic vulnerabilities are not fully understood, partly due to the lack of reliable patient-derived models. In this study, we attempted to establish organoid cultures from two clinically and pathologically unusual cases of MPNST using a modified air–liquid interface method. A stable organoid line was successfully generated from one case, and a corresponding organoid-derived xenograft (ODX) model was established. Both the organoid and ODX retained the histological, immunophenotypic, and genomic features of the original tumor. Comparative molecular analyses revealed shared copy number alterations involving NF1 and SUZ12 in both cases, suggesting underlying biological similarity. In the organoid-forming case, whole-exome and transcriptomic analyses identified a loss-of-function alteration in PTCH1 and activation of the Sonic Hedgehog (SHH) signaling pathway. Consistent with these findings, treatment with the Smoothened inhibitor vismodegib significantly suppressed organoid growth and downregulated SHH-related gene expression. These results indicate that SHH pathway activation may represent a therapeutically actionable vulnerability in a subset of MPNST. Our study establishes a patient-derived organoid model of MPNST and highlights its utility as a preclinical platform for investigating tumor biology and evaluating targeted therapies in this rare malignancy.

  • Establishment of a ZFP64::NCOA3 fusion-positive spindle cell/sclerosing rhabdomyosarcoma organoid model and evaluation of fusion-gene dependency

    by Ryota Miyamoto, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Hideaki Sabe, Yusuke Yoshimura, Haruna Takami, Rie Suzuki, et al.

  • Open Access

    Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability

    by Haruki Matsuoka, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Hideaki Sabe, Yusuke Yoshimura, Haruna Takami, Rie Suzuki, et al.

    Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive soft tissue sarcoma of presumed peripheral nerve sheath origin, for which effective systemic therapies remain limited. The biological mechanisms underlying its progression and therapeutic vulnerabilities are not fully understood, partly due to the lack of reliable patient-derived models. In this study, we attempted to establish organoid cultures from two clinically and pathologically unusual cases of MPNST using a modified air–liquid interface method. A stable organoid line was successfully generated from one case, and a corresponding organoid-derived xenograft (ODX) model was established. Both the organoid and ODX retained the histological, immunophenotypic, and genomic features of the original tumor. Comparative molecular analyses revealed shared copy number alterations involving NF1 and SUZ12 in both cases, suggesting underlying biological similarity. In the organoid-forming case, whole-exome and transcriptomic analyses identified a loss-of-function alteration in PTCH1 and activation of the Sonic Hedgehog (SHH) signaling pathway. Consistent with these findings, treatment with the Smoothened inhibitor vismodegib significantly suppressed organoid growth and downregulated SHH-related gene expression. These results indicate that SHH pathway activation may represent a therapeutically actionable vulnerability in a subset of MPNST. Our study establishes a patient-derived organoid model of MPNST and highlights its utility as a preclinical platform for investigating tumor biology and evaluating targeted therapies in this rare malignancy.

  • Open Access

    Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression

    by Toru Wakamatsu, Yoshiki Yamada, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Kazuko Shizuma, Rie Suzuki, Hironari Tamiya, Yoshinori Imura, et al.

    Although several studies have investigated synovial sarcoma using established cell lines and mouse models, effective treatments remain limited. We treated five patients with synovial sarcoma at our institute between 2022 and 2023, and resected tumor specimens were cultured using a modified air–liquid interface organoid method. After serial passaging and xenografting into NOD-scid IL2Rgnull (NSG) mice, patient-derived organoid lines were successfully established in three of five cases. These organoids exhibited stable propagation, tumorigenicity, and retained histological and genetic features of the original tumors, including SS18–SSX fusion confirmed by polymerase chain reaction and Sanger sequencing. We then evaluated the organoids’ response to a ferroptosis-inducing agent previously reported to be effective in synovial sarcoma. Despite low malic enzyme 1 ( ME1 ) expression, which has been associated with ferroptosis sensitivity, the established organoids were resistant to treatment. This unexpected result suggests additional mechanisms of resistance and highlights the complexity of ferroptosis regulation in synovial sarcoma. Our findings demonstrate the feasibility of establishing synovial sarcoma organoids using a modified culture method and suggest their potential as preclinical models for drug screening and mechanistic studies. These models provide a valuable resource for the development of novel therapeutic strategies for this rare and aggressive tumor.


  • Open Access

    Chondrosarcoma organoids reveal SHH pathway activation driven by PTCH1 and BCOR alterations

    by Haruna Takami, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Kazuma Kiyotani, Yusuke Yoshimura, Rie Suzuki, Hironari Tamiya, et al.

    Chondrosarcoma is the second most common malignant bone tumor, characterized by the production of cartilaginous matrix and a high degree of resistance to conventional therapies such as chemotherapy and radiotherapy. Effective treatment options remain limited, highlighting the urgent need for preclinical models to explore novel therapeutic approaches. This study aimed to establish patient-derived organoid (PDO) models of chondrosarcoma and to investigate their utility in elucidating molecular mechanisms and drug responses. Chondrosarcoma specimens were collected from patients and cultured using a modified air–liquid interface (ALI) organoid method. The resulting PDO were serially expanded in vitro and transplanted into NOD-SCID IL2Rgnull mice for in vivo validation. Histological and genetic analyses were performed to compare organoids with the corresponding primary tumors. Whole-exome profiling was used to identify genetic alterations. Organoid-based drug sensitivity testing was conducted using vismodegib, a Sonic Hedgehog (SHH) pathway inhibitor. Two PDO lines were successfully established. Organoid-derived xenografts preserved the histological and genetic features of the parental tumors. Genomic profiling revealed loss-of-function mutations in PTCH1 and BCOR , suggesting activation of the Sonic Hedgehog signaling pathway. Consistently, vismodegib exhibited strong in vitro antitumor activity, indicating functional pathway dependence. We established the first PDO models of chondrosarcoma that faithfully recapitulate key tumor features. These models provide a valuable preclinical platform for dissecting molecular pathogenesis and for advancing the development of targeted therapeutic strategies in this intractable malignancy.


  • Open Access

    Chondrosarcoma Organoids Reveal Targetable SHH Pathway Activation via PTCH1 Alterations

    by Haruna Takami, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Kazuma Kiyotani, Yusuke Yoshimura, Rie Suzuki, Hironari Tamiya, et al.

    Purpose Chondrosarcoma is the second most common malignant bone tumor, characterized by the production of cartilaginous matrix and a high degree of resistance to conventional therapies such as chemotherapy and radiotherapy. Effective treatment options remain limited, highlighting the urgent need for preclinical models to explore novel therapeutic approaches. This study aimed to establish patient-derived chondrosarcoma organoid models and to investigate their utility in elucidating molecular mechanisms and drug responses. Methods Chondrosarcoma specimens were collected from patients and cultured using a modified air–liquid interface (ALI) organoid method. The resulting organoids were serially expanded in vitro and transplanted into NOD-SCID IL2Rgnull mice for in vivo validation. Histological and genetic analyses were performed to compare organoids with the corresponding primary tumors. Whole-exome profiling was used to identify genetic alterations. Organoid-based drug sensitivity testing was conducted using vismodegib, a Sonic Hedgehog (SHH) pathway inhibitor. Results Two patient-derived organoid lines were successfully established. Organoid-derived xenografts preserved the histological and genetic features of the parental tumors. Genomic profiling revealed loss-of-function mutations in PTCH1 and BCOR , suggesting activation of the SHH signaling pathway. Consistently, vismodegib exhibited strong in vitro antitumor activity, indicating functional pathway dependence. Conclusion We established the first patient-derived chondrosarcoma organoid models that faithfully recapitulate key tumor features. These models provide a valuable preclinical platform for dissecting molecular pathogenesis and for advancing the development of targeted therapeutic strategies in this intractable malignancy.

  • Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway

    by Yusuke Yoshimura, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Ryota Miyamoto, Rie Suzuki, Hironari Tamiya, Shigeki Kakunaga, et al.

    Histiocytic sarcoma is an extremely rare and aggressive malignant neoplasm characterized by immunophenotypic features of mature histiocytes. The mechanisms underlying its malignant transformation remain poorly understood; consequently, the development of effective therapies remains limited. Resected histiocytic sarcoma specimens were cultured using a modified air–liquid interface organoid method, serially passaged, and xenografted into NOD-scid IL2Rgnull mice. Tumors formed by xenografted organoids retained histological and genetic similarities with the original tumor. Genomic analysis revealed the activation of the Sonic Hedgehog signaling pathway and amplification of Yes-associated protein 1, a key effector of the Hippo pathway. Accordingly, we evaluated the sensitivity of the organoids to the Sonic Hedgehog inhibitor vismodegib and Yes-associated protein 1 inhibitor verteporfin, both of which demonstrated potent in vitro antitumor activity in organoid cultures. This model offers a valuable preclinical platform for investigating the molecular pathology of this rare malignancy and accelerating the development of targeted therapies.


  • Open Access

    Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression

    by Toru Wakamatsu, Yoshiki Yamada, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Kazuko Shizuma, Rie Suzuki, Hironari Tamiya, Yoshinori Imura, et al.

    Although several studies have investigated synovial sarcoma using established cell lines and mouse models, effective treatments remain limited. We treated five patients with synovial sarcoma at our institute between 2022 and 2023, and resected tumor specimens were cultured using a modified air–liquid interface organoid method. After serial passaging and xenografting into NOD-scid IL2Rgnull (NSG) mice, patient-derived organoid lines were successfully established in three of five cases. These organoids exhibited stable propagation, tumorigenicity, and retained histological and genetic features of the original tumors, including SS18–SSX fusion confirmed by polymerase chain reaction and Sanger sequencing. We then evaluated the organoids’ response to a ferroptosis-inducing agent previously reported to be effective in synovial sarcoma. Despite low malic enzyme 1 (ME1) expression, which has been associated with ferroptosis sensitivity, the established organoids were resistant to treatment. This unexpected result suggests additional mechanisms of resistance and highlights the complexity of ferroptosis regulation in synovial sarcoma. Our findings demonstrate the feasibility of establishing synovial sarcoma organoids using a modified culture method and suggest their potential as preclinical models for drug screening and mechanistic studies. These models provide a valuable resource for the development of novel therapeutic strategies for this rare and aggressive tumor.

  • Open Access

    Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types

    by Hironari Tamiya, Kazumi Nishino, Yuji Kato, Reina Nakahashi-Kato, Yurika Kosuga-Tsujimoto, Shota Kinoshita, Rie Suzuki, Makiyo Watanabe, Toru Wakamatsu, Shigeki Kakunaga, et al.

    Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival. Methods: A total of 539 cancer patients were retrospectively analyzed to identify significant independent factors in post-bone metastasis survival. Results: Among the overall population, patients with the following cancers had a median survival longer than 24 months: thyroid, 97.2 months; breast, 51.5 months; prostate, 47.2 months; and kidney, 38.8 months. In contrast, median post-bone metastasis survival was significantly shorter in gastrointestinal (GI) (6.5 months), head and neck (6.3 months), and urinary tract (3.4 months) cancers. In non-small cell lung cancer (NSCLC), the log-rank test demonstrated that the epidermal growth factor receptor (EGFR) mutation was a significant factor for post-bone metastasis survival: EGFR mutation (−) n = 67, median post-bone metastasis survival 11.5 months (95% CI: 6.0–15.2); EGFR mutation (+) n = 39, median post-bone metastasis survival 28.8 months (95% CI: 18.1–35.7) (p < 0.05). Intriguingly, treatment with BMA was a significant positive prognostic factor: BMA (−) n = 203, median post-bone metastasis survival 7.8 months (95% CI: 5.8–12.5); BMA (+) n = 336, median post-bone metastasis survival 21.9 months (95% CI: 16.1–26.4) (p < 0.001). Moreover, the Cox proportional hazards model showed that this was particularly evident in cancer types with poor prognosis such as GI cancer (hazard ratio [HR]: 0.62, 95% CI: 0.40–0.95; p < 0.05) and NSCLC without the epidermal growth factor receptor (EGFR) mutation (HR: 0.56, 95% CI: 0.34–0.91; p < 0.05). Conclusions: Treatment with BMA is recommended not only for the prevention and/or treatment of SRE, but also may have a positive impact on post-bone metastasis survival, particularly in cancers with typically poor post-bone metastasis survival such as GI cancer and NSCLC without the EGFR mutation.